{"transactions":[{"id":1457621,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-07-09T18:04:39.000Z","date":"2024-07-05","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":130000,"derivative":{"exercise_price":19.73,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-082529","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000095017024082529/ownership.xml","form_type":"4"}},{"id":1457620,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-07-09T18:04:39.000Z","date":"2024-07-05","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":44.08,"value":661200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.08 per share. The range of sales prices on the transaction date was $43.71 to $44.41 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":29259,"source":{"system":"sec-edgar","filing":"0000950170-24-082529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000095017024082529/ownership.xml","form_type":"4"}},{"id":1457619,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-07-09T18:04:39.000Z","date":"2024-07-05","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":19.73,"value":295950.0,"ownership":{"direct":true},"balance_after":44259,"source":{"system":"sec-edgar","filing":"0000950170-24-082529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000095017024082529/ownership.xml","form_type":"4"}},{"id":1470745,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-06-24T17:08:02.000Z","date":"2024-06-21","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":145000,"derivative":{"exercise_price":19.73,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-076871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000095017024076871/ownership.xml","form_type":"4"}},{"id":1470744,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-06-24T17:08:02.000Z","date":"2024-06-21","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":44.66,"value":669900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.66 per share. The range of sales prices on the transaction date was $43.96 to $45.11 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":29259,"source":{"system":"sec-edgar","filing":"0000950170-24-076871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000095017024076871/ownership.xml","form_type":"4"}},{"id":1470743,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-06-24T17:08:02.000Z","date":"2024-06-21","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":19.73,"value":295950.0,"ownership":{"direct":true},"balance_after":44259,"source":{"system":"sec-edgar","filing":"0000950170-24-076871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000095017024076871/ownership.xml","form_type":"4"}},{"id":1566099,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-20T18:34:05.000Z","date":"2024-03-18","kind":"tax_withholding","planned":true,"acquired":false,"shares":1741,"price":38.14,"value":66401.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 1, 2023.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":29259,"source":{"system":"sec-edgar","filing":"0001209191-24-005011","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000120919124005011/doc4.xml","form_type":"4"}},{"id":1591907,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-06T20:18:41.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024."}],"balance_after":63000,"derivative":{"exercise_price":43.51,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001209191-24-004612","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000120919124004612/doc4.xml","form_type":"4"}},{"id":1591906,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-06T20:18:41.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025."}],"balance_after":31000,"source":{"system":"sec-edgar","filing":"0001209191-24-004612","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000120919124004612/doc4.xml","form_type":"4"}},{"id":1974116,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T16:47:10.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":65250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023."}],"balance_after":65250,"derivative":{"exercise_price":19.64,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":65250},"source":{"system":"sec-edgar","filing":"0001209191-23-015619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000120919123015619/doc4.xml","form_type":"4"}},{"id":1974115,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-03T16:47:10.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001209191-23-015619","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000120919123015619/doc4.xml","form_type":"4"}},{"id":2339958,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-10T16:51:04.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":160000,"derivative":{"exercise_price":19.73,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-22-017938","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799357/000120919122017938/doc4.xml","form_type":"4"}},{"id":2656499,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-06-24T22:44:06.000Z","date":"2021-06-22","kind":"sale","acquired":false,"shares":3625,"price":89.22,"value":323422.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":105750,"source":{"system":"sec-edgar","filing":"0001209191-21-043137","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121043137/doc4.xml","form_type":"4"}},{"id":2912910,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":89095,"kind":"person","name":"Hassard James","position":1,"cik":"0001799357","reported_name":"Hassard James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-08T23:05:07.000Z","date":"2021-01-07","kind":"sale","acquired":false,"shares":15625,"price":75,"value":1171875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":109375,"source":{"system":"sec-edgar","filing":"0001209191-21-002801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121002801/doc4.xml","form_type":"4"}}]}